Your browser doesn't support javascript.
loading
Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project.
Civallero, Monica; Schroers-Martin, Joseph G; Horwitz, Steven; Manni, Martina; Stepanishyna, Yana; Cabrera, Maria Elena; Vose, Julie; Spina, Michele; Hitz, Felicitas; Nagler, Arnon; Montoto, Silvia; Chiattone, Carlos; Skrypets, Tetiana; Perez Saenz, M Angeles; Priolo, Giorgio; Luminari, Stefano; Lymboussaki, Athina; Pavlovsky, Astrid; Marino, Dario; Liberati, Marina; Trotman, Judith; Mannina, Donato; Federico, Massimo; Advani, Ranjana.
Afiliação
  • Civallero M; CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy.
  • Schroers-Martin JG; Division of Oncology, Department of Medicine, Stanford University, Stanford, California, USA.
  • Horwitz S; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
  • Manni M; Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
  • Stepanishyna Y; Department of Bone Marrow Transplant, National Cancer Institute, Kyiv, Ukraine.
  • Cabrera ME; Sección Hematología, Hospital del Salvador, Universidad de Chile, Santiago, Chile.
  • Vose J; Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Spina M; Division of Medical Oncology and Immune-Related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  • Hitz F; Department of Oncology/Haematology, The Swiss Group for Clinical Cancer Research, Cantonal Hospital, St Gallen, Switzerland.
  • Nagler A; Department of Bone Marrow Transplantation, Tel-Aviv University, Tel-Aviv, Israel.
  • Montoto S; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
  • Chiattone C; Higienopolis and Santa Casa Medical School of Sao Paulo, Samaritano Hospital, São Paulo, Brazil.
  • Skrypets T; Hematology and Cell Therapy Department, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy.
  • Perez Saenz MA; Department of Hematology, Health Research Institute IIS-FJD, Fundacion Jimenez Diaz University Hospital, Madrid, Spain.
  • Priolo G; Hematology 2, San Giovanni Battista Hospital and University, Turin, Italy.
  • Luminari S; Hematology Unit, Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, Italy.
  • Lymboussaki A; CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy.
  • Pavlovsky A; Fundación para Combatir la Leucemia (FUNDALEU), Centro de Hematología Pavlovsky, Buenos Aires, Argentina.
  • Marino D; Department of Oncology, Oncology 1 Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
  • Liberati M; A.O. Santa Maria, S.C. di Oncoematologia di Terni, Università Degli Studi di Perugia, Perugia, Italy.
  • Trotman J; Concord Repatriation General Hospital, University of Sydney, Concord, New South Wales, Australia.
  • Mannina D; Hematology Unit, AO Papardo, Messina, Italy.
  • Federico M; CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy.
  • Advani R; Division of Oncology, Department of Medicine, Stanford University, Stanford, California, USA.
Br J Haematol ; 205(1): 166-174, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38532575
ABSTRACT
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, a subset of patients experience durable disease control, and little is known regarding long-term outcomes. The International T-cell Lymphoma Project (ITCLP) is the largest prospectively collected cohort of patients with PTCLs, providing insight into clinical outcomes at academic medical centres globally. We performed a long-term outcome analysis on patients from the ITCLP with available 10-year follow-up data (n = 735). The overall response rate to first-line therapy was 68%, while 5- and 10-year overall survival estimates were 49% and 40% respectively. Most deaths occurred prior to 5 years, and for patients alive at 5 years, the chance of surviving to 10 years was 84%. However, lymphoma remained the leading cause of death in the 5- to 10-year period (67%). Low-risk International Prognostic Index and Prognostic Index for T-cell lymphoma scores both identified patients with improved survival, while in multivariate analysis, age >60 years and Eastern Cooperative Oncology Group performance status 2-4 were associated with inferior outcomes. The favourable survival seen in patients achieving durable initial disease control emphasizes the unmet need for optimal front-line therapeutic approaches in PTCLs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_lymphomas_multiple_myeloma Assunto principal: Linfoma de Células T Periférico Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_lymphomas_multiple_myeloma Assunto principal: Linfoma de Células T Periférico Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália
...